文献速递炎症性肠病

非经典单核细胞经α4β7整合素归巢至肠道介导巨噬细胞依赖性肠创面愈合

Non-classical monocyte homing to the gut via α4β7 integrin mediates macrophage-dependent intestinal wound healing.
PubMed 文献 · Gut · 2019-05-15

研究探讨α4β7整合素在单核细胞肠道归巢中的作用及治疗性抑制对肠创面愈合的影响。发现非经典单核细胞表达α4β7并依赖其归巢至肠道,该归巢受损与创面愈合延迟和愈合相关巨噬细胞减少相关;维得利珠单抗治疗IBD患者外周血非经典单核细胞增加。

要点

  • 非经典单核细胞表达α4β7整合素,经典单核细胞不表达。
  • α4β7依赖的肠道归巢受损与创面愈合延迟及愈合巨噬细胞减少相关。
  • 维得利珠单抗治疗IBD患者外周血非经典单核细胞增加。

核心结论

  • 抗α4β7治疗在IBD中除影响淋巴细胞外,也靶向非经典单核细胞;其肠道归巢受损可能减少愈合巨噬细胞,并可能解释部分研究中观察到的维得利珠单抗治疗患者术后并发症增加。

研究设计与样本

  • 研究采用流式细胞术和免疫组化检测IBD患者及对照外周血单核细胞亚群和肠道巨噬细胞亚群的归巢标志物表达。
  • 采用动态黏附实验和体内肠道归巢实验评估整合素功能。
  • 在α4β7整合素缺陷或清除的小鼠中研究体内创面愈合。

主要发现

  • 经典与非经典单核细胞在归巢标志物表达上呈明显二分,α4β7整合素在人及小鼠非经典单核细胞上表达,经典单核细胞不表达。
  • 单核细胞表达的α4β7整合素对与黏膜血管地址素细胞黏附分子1的动态黏附及体内肠道归巢具有功能重要性。
  • α4β7依赖的肠道归巢受损与创面愈合减少(效应量约20%)和延迟相关,并抑制创面周边愈合巨噬细胞的存在。
  • 临床接受维得利珠单抗治疗的IBD患者外周血非经典单核细胞增加。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To study the role of α4β7 integrin for gut homing of monocytes and to explore the biological consequences of therapeutic α4β7 inhibition with regard to intestinal wound healing. DESIGN: We studied the expression of homing markers on monocyte subsets in the peripheral blood and on macrophage subsets in the gut of patients with IBD and controls with flow cytometry and immunohistochemistry. Integrin function was addressed with dynamic adhesion assays and in vivo gut homing assays. In vivo wound healing was studied in mice deficient for or depleted of α4β7 integrin. RESULTS: Classical and non-classical monocytes were clearly dichotomous regarding homing marker expression including relevant expression of α4β7 integrin on human and mouse non-classical monocytes but not on classical monocytes. Monocyte-expressed α4β7 integrin was functionally important for dynamic adhesion to mucosal vascular addressin cell adhesion molecule 1 and in vivo gut homing. Impaired α4β7-dependent gut homing was associated with reduced (effect size about 20%) and delayed wound healing and suppressed perilesional presence of wound healing macrophages. Non-classical monocytes in the peripheral blood were increased in patients with IBD under clinical treatment with vedolizumab. CONCLUSION: In addition to reported effects on lymphocytes, anti-α4β7 therapy in IBD also targets non-classical monocytes. Impaired gut homing of such monocytes might lead to a reduction of wound healing macrophages and could potentially explain increased rates of postoperative complications in vedolizumab-treated patients, which have been observed in some studies.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Schleier L, Wiendl M, Heidbreder K, et al. Non-classical monocyte homing to the gut via α4β7 integrin mediates macrophage-dependent intestinal wound healing. Gut. 2019. PMID: 31092589. doi:10.1136/gutjnl-2018-316772

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。